Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03589326 · ClinicalTrials.gov registry record · Phase 3
A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia
A Phase 3 study of Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Ph+ ALL, sponsored by Takeda.
- Active
- Registry status
- Phase 3
- Development phase
- 245
- Enrollment target
- 20
- Study locations
NCT03589326: Active Phase 3 study of Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Ph+ ALL, sponsored by Takeda.
NCT03589326 is a Phase 3 study of Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Ph+ ALL that is active but no longer recruiting, run by Takeda. The registered enrollment target is 245 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (68% lower). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03589326, a Phase 3 study of Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Ph+ ALL, is active but no longer recruiting, sponsored by Takeda.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 245 participants
- Enrollment target
- 20
- Study locations
Study Summary
In this study, adults with newly-diagnosed Philadelphia Chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) will receive first-line therapy of ponatinib or imatinib. The main aim of this study is to compare the number of participants on each treatment that show no signs of disease. Participants will take tablets of either ponatinib or imatinib at the same time each day combined with reduced-intensity chemotherapy for up to 20 months. Then, they will continue with single-agent therapy (ponatinib or imatinib) until they meet the discontinuation criteria from the study.
Primary Outcome
MRD-negative CR was achieved when a participant met the criteria for both MRD negativity and CR. MRD-negativity: ≤0.01 % breakpoint cluster region-Abelson (BCR-ABL1/ABL1), or undetectable BCR-ABL1 transcripts in complementary deoxyribonucleic acid (cDNA) with ≥ 10,000 ABL1 transcripts. CR: meeting all the following for at least 4 weeks (that is no recurrence):1. No circulating blasts and less than (\<) 5% blasts in the bone marrow (BM). 2. Normal maturation of all cellular components in the BM.
Conditions Studied
Interventions
- DRUG Dexamethasone
- DRUG Vincristine
- DRUG Cytarabine
- DRUG Imatinib
- DRUG Ponatinib
Study Locations (20)
New York
- Roswell Park Cancer Institute - Buffalo
- Monter Cancer Center - New Hyde Park
- Stony Brook University Medical Center - Stony Brook
California
- City of Hope - Duarte - Duarte
- University of California Los Angeles - Los Angeles
Indiana
- Indiana University - Indianapolis
- Indiana Blood & Marrow Transplantation - Indianapolis
Texas
- The University of Texas MD Anderson Cancer Center - Houston
- Methodist Hospital - San Antonio
Other
- Sanatorio Allende - Córdoba
- Hospital Privado Centro Medico de Cordoba - Córdoba
Victoria
- Box Hill Hospital - Box Hill
- Monash Medical Centre - Clayton
Alabama
- University of Alabama at Birmingham - Birmingham
Georgia
- Augusta University Georgia Cancer Center - Augusta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 245 participants |
| Start Date | 2018-10-04 |
| Est. Completion | 2027-07-31 |
| Phase | Phase 3 |
What the registry record for NCT03589326 still lists
NCT03589326 is an interventional study that assigns participants to a tested intervention. The registered 245 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (68% lower).
The record links to 1 condition, with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Ph+ ALL appearing as the primary indexed condition, and to 5 interventions - of which Dexamethasone is the first listed.
NCT03589326 names 20 study sites across 13 states, led by New York, California, Indiana.
Frequently Asked Questions
What is clinical trial NCT03589326 about?
NCT03589326 is a clinical study titled "A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia". In this study, adults with newly-diagnosed Philadelphia Chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) will receive first-line therapy of ponatinib or imatinib. The main aim of this study is to compare the number of participants on each treatment that show no signs of disease. Particip...
What is the current status of trial NCT03589326?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 245 participants. The study started on 2018-10-04. Estimated completion is 2027-07-31.
What conditions does trial NCT03589326 study?
This clinical trial studies the following conditions: Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Ph+ ALL.
What interventions are being tested in trial NCT03589326?
The interventions under investigation include: Dexamethasone (DRUG), Vincristine (DRUG), Cytarabine (DRUG), Imatinib (DRUG), Ponatinib (DRUG).
Who is sponsoring clinical trial NCT03589326?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03589326 being conducted?
This trial has 20 study locations across Alabama, California, Georgia, Indiana, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Ph+ ALL
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03589326's enrollment target sits among peer trials
245 1268th of 2000 higher than 732 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03645928 · 245 participants · Phase 2
Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors
- NCT04718168 · 245 participants · NA
GORE® ENFORM Biomaterial Product Study
- NCT05145127 · 245 participants · Phase 3
Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors
- NCT05446259 · 245 participants
Degenerative Cervical Myelopathy Repository
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI